Efficacy Of Inebilizumab In Patients With Nmosd With Fc Receptor Iii-A Polymorphisms

Efficacy of inebilizumab in patients with NMOSD with Fc receptor III-A polymorphisms

Distinctive attributes and efficacy of inebilizumab in NMOSD

Inebilizumab as a Potential Therapy for Autoimmune Encephalitis

Consistent efficacy of inebilizumab across newly presenting and previously treated NMOSD cases

The Safety and Effective of Inebilizumab in African American NMOSD Patients

Efficacy of Switching From to Inebilizumab in Rituximab in NMOSD

Updates on N-MOmentum: inebilizumab versus placebo in patients with NMOSD

Inebilizumab Treatment in Newly Diagnosed NMOSD Patients

Inebilizumab in AQP4+ NMOSD patients with history of immunosuppression treatment: N-MOmentum study

Long Term Benefits of Inebilizumab Revealed in N MOmentum Analysis

Effector Function Seminar Series: Mouse models of effector function/FcR & IgG allotype polymorphisms

FNIH

SAkura: long-term safety and efficacy of satralizumab for NMOSD

NMOSD Multidisciplinary Approach Webinar, 25 June 2021 - Dr. Suzan Ibrahim Noori

MCO Healthcare Conferences

New agents under investigation to treat AQP4-positive NMOSD

Bruce Cree, MD, PhD, MAS: Inebilizumab for NMOSD Treatment

Inebilizumab: Proposed Mechanism of Action For Treating NMOSD

AAN 2021 Highlights: Two-Year Efficacy and Safety Data with Inebilizumab To Treat NMOSD

Satralizumab in patients with NMOSD and concomitant autoimmune diseases

Bruce Cree, MD, PhD, MAS: Inebilizumab in Neuromyelitis Optica Spectrum Disorder